vedolizumab,erdafitinib
janssen,takeda
[' vedo', 'ibd', 'erda', 'vedo', 'vedolizumab']
vedolizumab is highly effective in reducing postoperative endoscopic recurrence! #ecco2023 data presented by prof geert d haens here in copenhagen 
M.D., PhD., Colorectal surgeon and IBD Specialist! School of Medicine, Ribeirão Preto, University of São Paulo